Cytosorbents Corporation
CTSO
$1.10
-$0.03-2.66%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 20.35% | 3.47% | 11.65% | 13.12% | 43.32% |
| Total Depreciation and Amortization | 39.56% | 61.55% | 85.26% | 79.09% | 3.23% |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | -- | -- |
| Total Other Non-Cash Items | -17.46% | 195.98% | -14.06% | -64.84% | -93.16% |
| Change in Net Operating Assets | -618.20% | -505.08% | -239.10% | 166.29% | 367.81% |
| Cash from Operations | 10.18% | 3.97% | -0.66% | 23.30% | 27.47% |
| Capital Expenditure | 52.66% | 73.88% | 98.75% | 91.16% | 91.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -5.74% | -8.76% | 24.03% | -8.12% | 32.10% |
| Cash from Investing | 32.31% | 56.29% | 93.95% | 85.50% | 87.30% |
| Total Debt Issued | 200.00% | 200.00% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 441.75% | 699.31% | 1,922.96% | -- | 24,775.82% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | 194.26% | 234.40% | 132.54% | 191.84% | 6,088.21% |
| Foreign Exchange rate Adjustments | -156.29% | -202.60% | 27.74% | 62.05% | 136.75% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 114.96% | 100.61% | 55.60% | 72.60% | 61.43% |
